





Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-022-02182-7>.
Published online 23 January 2023.

<https://doi.org/10.1038/s41591-023-02306-7>

Published online: 17 March 2023

Sham Mailankody , Jeffrey V. Matous, Saurabh Chhabra , Michaela Liedtke, Surbhi Sidana , Olalekan O. Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Myo Htut, Erin E. Karski, Wade Lovelace, Myles Dillon, Eric Butz, Wendy Ying, Arun Balakumaran & Shaji K. Kumar 

In the version of this article initially published, the clinical trials registration number [NCT04093596](https://clinicaltrials.gov/ct2/show/study/NCT04093596) was missing from the Abstract and has now been amended in the HTML and PDF versions of the article.








© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-019-0628-7>.
Published online 4 November 2019.

<https://doi.org/10.1038/s41591-023-02312-9>

Published online: 21 March 2023

Thomas Powles , Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb , Michiel S. Van Der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz , Andrew Protheroe , Alain Ravaud, Denis Maillet, Maria Jose Mendez , Cristina Suarez, Mark Linch, Aaron Prendergast , Pieter-Jan van Dam , Diana Stanoeva, Sofie Daelemans, Sanjeev Mariathasan, Joy S. Tea , Kelly Mousa, Romain Banchereau & Daniel Castellano

In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023